Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
NCT ID NCT07659379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of a parent gotistobart trial. The study does not test a new treatment but monitors ongoing effects and outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gotistobart (a humanized anti-CTLA4 antibody)
- What this could lead to
- If successful, this study could confirm that gotistobart is safe and effective for long-term use in advanced solid tumors, potentially offering a new treatment option.
- What could go wrong
- This is a small extension study (20 participants) focused on long-term follow-up, not a new treatment test. Results may not apply to all patients, and side effects remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?